Concepedia

Sheri Shirazian

SS

Statistics

Publications

2

Citations

2.5K

H-Index

2

Active since

2003

Affiliations

Amgen (United States)(Current)

Sheri Shirazian is an author at Amgen (United States) specializing in vascular biology, pharmacotherapy, and tumor biology.

Top concepts

MedicinePharmacologyTumor BiologyPharmacotherapyVascular BiologyRadiation OncologyOncologyAngiogenesisBiochemistryCell Biology

Publications per year

2003–2003

2

Publications

2

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Tumor Xenografts, Mouse Xenograft Models, Active Dose +18

Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

Li Sun, Chris Liang, Sheri Shirazian et al. · Journal of Medicinal Chemistry · 2003 · 518 citations · Full text

Chemoprevention Strategy, Weakly Basic Analogues, Pharmacotherapy +20

1–2 of 2